Merck KGaA goes toe to toe with Novartis as FDA green-lights MET inhibitor
Merck KGaA has clinched the big FDA endorsement for its MET inhibitor tepotinib, setting the stage for a market showdown with Novartis.
Tepmetko is the second oral drug to be granted accelerated approval in the US to treat metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition exon 14 skipping alterations, following Tabrecta’s, or capmatinib’s OK in May. Weeks before that, though, it became the first MET-targeted therapy to be approved anywhere in the world when Japan gave a thumbs up to Merck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
